Ifosfamide is an alkylating drug indicated for use in combination with other approved antineoplastic agents for third-line chemotherapy of recurrent or refractory germ cell testicular cancer. It should be used in combination with mesna to prevent hemorrhagic cystitis. Additionally, it is used as a component of chemotherapeutic regimens for the treatment of cervical cancer and soft tissue sarcomas. Ifosfamide has also been used in the treatment of a variety of other cancers including osteosarcoma, bladder cancer, ovarian cancer, small cell lung cancer, non-Hodgkin’s lymphoma, and breast cancer.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Ifosfamide, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.